Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony P Conley

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Cancers|March 13, 2024
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, et al.
Cancer Research Communications|May 21, 2026
Drug screening of sarcoma cells: finding shared sensitivitiesHannah C Beird, Carl Ho, Roberto Cardenas-Zuniga, et al.
Cancers|May 11, 2024
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center ExperienceLewis F Nasr, Marianne Zoghbi, Rossana Lazcano, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2026
A pooled analysis of phase 2 clinical trials in advanced chordomaGregory M Cote, Corrine F Elliott, Astrid Lipplaa, et al.
Neuro-Oncology|March 8, 2026
Oncolytic Adenoviral Infection of Chordoma Achieves Treatment Efficacy Associated with Immunologic Response and Tumor Microenvironmental AlterationXizi Wu, Daniel Ledbetter, Jen-Wei Tsai, et al.
Molecular Cancer Therapeutics|April 1, 2024
Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient LeiomyosarcomasMichael S Nakazawa, Ian M Silverman, Victoria Rimkunas, et al.
Cancer|July 6, 2022
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyVinod Ravi, Aparna Subramaniam, Jing Zheng, et al.
Nature Communications|February 22, 2020
Immuno-genomic landscape of osteosarcomaChia-Chin Wu, Hannah C Beird, J Andrew Livingston, et al.
Cancer|April 5, 2023
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancerBlessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Cancers|March 13, 2024
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, et al.
Cancer Research Communications|May 21, 2026
Drug screening of sarcoma cells: finding shared sensitivitiesHannah C Beird, Carl Ho, Roberto Cardenas-Zuniga, et al.
Cancers|May 11, 2024
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center ExperienceLewis F Nasr, Marianne Zoghbi, Rossana Lazcano, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2026
A pooled analysis of phase 2 clinical trials in advanced chordomaGregory M Cote, Corrine F Elliott, Astrid Lipplaa, et al.
Neuro-Oncology|March 8, 2026
Oncolytic Adenoviral Infection of Chordoma Achieves Treatment Efficacy Associated with Immunologic Response and Tumor Microenvironmental AlterationXizi Wu, Daniel Ledbetter, Jen-Wei Tsai, et al.
Molecular Cancer Therapeutics|April 1, 2024
Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient LeiomyosarcomasMichael S Nakazawa, Ian M Silverman, Victoria Rimkunas, et al.
Cancer|July 6, 2022
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyVinod Ravi, Aparna Subramaniam, Jing Zheng, et al.
Nature Communications|February 22, 2020
Immuno-genomic landscape of osteosarcomaChia-Chin Wu, Hannah C Beird, J Andrew Livingston, et al.
Cancer|April 5, 2023
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancerBlessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Pageof 8